U.S. Supreme Court and Generic Drugs | TWIRx

This week, This Week in Pharmacy examines several stories shaping the business, clinical, and legal future of pharmacy practice.

In TWIRx News from Pharmacy Times from Megan Maroney, PharmD, BCPP, FAAPP, focused on antidepressant use, withdrawal concerns, deprescribing, and shared decision-making. The key takeaway: patients should never stop antidepressants abruptly. Pharmacists can play a vital role in reducing stigma, educating patients, and supporting safe conversations about tapering, side effects, and long-term treatment.

In health technology news, FDB research presented at the 2026 AMIA Amplify Informatics Conference found that patient-specific, risk-based medication guidance reduced pharmacy alert volume by 70% in a high-volume community pharmacy setting. The model consolidates alerts into one actionable message tied to the patient’s most relevant risk, helping reduce alert fatigue and improve workflow.

Finally, we review a federal court ruling in Eli Lilly’s lawsuit against Houston-based Empower Pharmacy over compounded tirzepatide versions of Mounjaro and Zepbound. The judge dismissed key federal trademark and Texas unfair competition claims, while allowing other state claims to continue.

Andy Crawford, with Keysource is back on TWIRx talking about the U.S. Supreme Court taking up Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., a case that could significantly affect generic drug competition. At issue is whether Hikma’s marketing materials and public communications around its generic version of Amarin’s fish oil-based cardiovascular drug improperly promoted a still-patented use. Hikma and the broader generic industry argue the case is about protecting “skinny label” rules, which allow generics to carve out patented indications while still bringing lower-cost medications to market. For pharmacists, the decision could influence generic availability, substitution confidence, pricing pressure, and how manufacturers communicate with providers and pharmacies.

Thanks to our sponsors, CassianRx and IPC, for supporting independent pharmacy, innovation, and the future of patient-centered care.